



One size does not fit all

Specific challenges posed by individual donor, recipient and transplant characteristics

8.30-10.30

Expanding the donor-pool and outcomes. The challenges of Donation after Circulatory Death (DCD) in the different Solid Organ Transplants

There is an imbalance between supply and demand in organ transplantation. Donation after Circulatory Death (DCD) has contributed to an increase of the donor organ pool and yields overall acceptable results in kidney, lung and liver transplantation. DCD heart transplantation seems to become a clinical reality as well, but faces its own problems. In this session, current challenges of DCD programs with respect to patient management are addressed.

Chairs: Robert Langer (Linz, Austria) and Oriol Bestard (Barcelona, Spain)

DCD in heart transplantation: are we there already?

Stephen R. Large (Cambridgeshire, UK)

Is DCD liver transplantation a good option in primary sclerosing cholangitis?

Constantino Fondevila (Barcelona, Spain)

Are DCD extended criteria donors acceptable in kidney transplantation?

Frederike J. Bemelman (Amsterdam, Netherlands)

Uncontrolled DCD in lung transplantation: an underused supply?

Eduardo Miñambres (Cantabria, Spain)

10.30-11.00

Break

11.00-13.00

New tools to improve transplant risk stratification and clinical perspectives. Are we there yet?

Precision medicine, in which health care interventions are tailored on the basis of individual characteristics, holds promise to improve the outcome of transplantation. Precision medicine in transplantation requires tools to stratify the risk for a strong allo-immune response and to predict the response to therapy. Latest insights on these topics and implications for therapy and patient management will be shared in this session.

Chairs: Klemens Budde (Berlin, Germany) and Marta Crespo Barrio (Barcelona, Spain)

Molecular histocompatibility assessment for de novo alloimmune risk stratification.

Jean Luc Taupin (Paris, France)

Biomarkers for immune risk stratification, from discovery to validation.

Maarten Naesens (Leuven, Belgium)

Pharmacogenomics to individualize tacrolimus dose regimens.

Teun Van Gelder (Rotterdam, Netherlands)

Can prediction of non-adherence lead to targeted interventions?

Fabienne Dobbels (Leuven, Belgium)



**CLINICAL
TRANSPLANTATION
DAY**

www.ctday.eu

13.00-13.45

Lunch

13.45-14.30

Free communication session (3 talks of the 3 best abstracts- 10+5 minutes' discussion each)

Chairs: Gjeir Mjoen (Oslo, Norway) and Licia Peruzzi (Turin, Italy)

14.30-16.30

New therapies in transplantation

Currently, the success of organ transplantation is mainly based on the use of powerful immunosuppressive drugs. While the use of available drugs can still be optimized, the search for more effective and/or less toxic agents, including cell-based therapies, continues. An expert overview will be given.

Chairs: Rainer Oberbauer (Vienna, Austria) and Luuk Hilbrands (Nijmegen, The Netherlands)

Tacrolimus based immunosuppression, for whom and with whom?

Julio Pascual (Barcelona, Spain)

Co-stimulation blockade as the everlasting promise?

Josep Grinyó (Barcelona, Spain)

New approaches to increase the access to transplantation in highly sensitized patients

Cell therapy, is there room for it?

16.30-16.45

Closing remarks